[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nsaid-non-steroidal-anti-inflammatory-drug\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nsaid-non-steroidal-anti-inflammatory-drug":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100630865","efficacy-of-chemically-distinct-nonsteroidal-anti-inflammatory-drugs-nsaids-and-pain-phenotypes-in-adhesive-capsulitis-100630865",false,"NCT07493226","Efficacy of Chemically Distinct Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Pain Phenotypes in Adhesive Capsulitis","Comparative Efficacy of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) With Distinct Chemical Structures in Shoulder Adhesive Capsulitis and the Role of Pain Phenotypes","Inclusion Criteria:\n\n1. Being between 18-75 years of age\n2. Having shoulder pain that has lasted for at least one month and being diagnosed with primary frozen shoulder\n3. Having a VAS pain level ≥ 4\u002F10\n4. Having ≥30 degrees of range of motion restriction in at least two planes (flexion, abduction, or external rotation)\n5. Not having any exclusion criteria and agreeing to participate in the study voluntarily\n\nExclusion Criteria:\n\n1. Patients with a history of shoulder trauma, those with musculoskeletal disorders characterized by pain and loss of function in the affected extremity (such as lateral epicondylitis, flexor tendon injury, de Quervein's tenosynovitis)\n2. Presence of neurological involvement such as stroke, brachial plexus injury, Parkinson's disease, and cervical spine injury with or without radiculopathy\n3. History of shoulder surgery, malignancy or tumor in the shoulder, those who have undergone shoulder manipulation\n4. Presence of shoulder arthritis, rotator cuff tear or other shoulder injuries, thoracic outlet syndrome\n5. Systemic disease affecting the shoulder region, severe degeneration or trauma (e.g., osteoarthritis, rheumatoid arthritis, history of labrum or articular cartilage injuries), inflammatory rheumatic diseases\n6. Those who have received steroid injections into the affected extremity within the last 3 months, those using oral steroids or NSAIDs, those receiving any surgical or interventional treatment, or Planned individuals:\n7. Those who are pregnant or lactating\n8. Those with uncontrolled diabetes, heart failure, uncontrolled systemic disease (liver disease, chronic kidney failure, significant endocrine disorders, etc.)\n9. Those with communication problems, severe psychiatric disorders\n10. Those allergic to NSAIDs or with any contraindications\n11. Those with bleeding, coagulation disorders, stomach ulcers, or symptomatic gastritis","ALL","18 Years","75 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients aged 18-75 years who present to a tertiary rehabilitation hospital with shoulder pain and restricted range of motion, and who consent to participate, will be included in the study. Eligibility will be determined based on predefined inclusion and exclusion criteria.\n\nEligible patients will be randomly assigned to receive one of several nonsteroidal anti-inflammatory drugs (NSAIDs) with differing chemical properties (e.g., diclofenac, meloxicam, or indomethacin), in combination with a home-based exercise program for shoulder adhesive capsulitis. Patients' sociodemographic data, as well as detailed clinical and examination findings and baseline outcomes, will be recorded. Patients will be informed about their condition, and modifications to activities of daily living will be recommended.Patients' pain phenotypes (nociceptive, neuropathic, nociplastic) will be categorized based on clinical history and questionnaires, and it will be determined which pain types derive greater benefit from NSAIDs.\n\nFollow-up assessments will be conducted at the end of the first and second weeks. At the first-week follow-up, pain intensity will be evaluated using the Visual Analog Scale (VAS). If the treatment is deemed effective (defined as a ≥3-point reduction or ≥50% decrease in VAS), the same NSAID will be continued for an additional week; otherwise, it will be switched to an alternative NSAID with a different biochemical profile (group). The outcomes assessments will be performed by a blinded evaluator to minimize bias.",[27,28,29,30,31,32],"Frozen Shoulder","Adhesive Capsulitis","Shoulder Pain","NSAID (Non-Steroidal Anti-Inflammatory Drug)","Nociplastic Pain","Neuropathic Pain",[34,35,36,37,38,39],"frozen shoulder","adhesive capsulitis","shoulder pain","pain phenotypes","exercises","Nonsteroidal Anti-Inflammatory Drugs","RECRUITING","2026-05-11",{"date":43,"type":44},"2026-05-14","ACTUAL",{"date":46,"type":44},"2026-04-01",{"date":48,"type":21},"2027-03-30",{"name":50,"class":51},"Konya Beyhekim Training and Research Hospital","OTHER_GOV",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":52},"100633944","phase-4-study-to-evaluate-the-efficacy-and-safety-of-fexuprazan-in-prevention-of-nsaids-induced-peptic-ulcer-100633944","NCT07533266","Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer","A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Fexuclue Tab. in Prevention of NSAIDs-induced Peptic Ulcer","Inclusion Criteria:\n\n1. Male and female adults aged ≥ 19 years at the time of informed consent\n2. Subjects who are diagnosed with musculoskeletal disease at screening and require continued treatment with NSAIDs for at least 24 weeks\n3. Subjects with at least one of the following risk factors for ulcer development at screening.\n4. Subjects who have no gastric or duodenal mucosal break or have ulcer in the scarring stage based on the EGD result at screening.\n\nExclusion Criteria:\n\n1. Subjects with esophagitis, gastroesophageal varix, esophagus, Barrett's esophagus, acute gastrointestinal bleeding and else based on the screening EGD results.\n2. Subjects who have undergone gastroduodenal surgery or total small bowel resection\n3. Subjects with history of clinically significant disease of hepatic, renal, nervous, pulmonary, endocrine, hemato-oncologic, cardiovascular or urinary system\n4. Subjects who have had a malignant tumor in the last 5 years\n5. Subjects who history of hypersensitivity to the IP ingredients, aspirin and NSAIDs","19 Years",{"count":62,"type":21},360,[64],"PHASE4","The study aims to demonstrate the preventive effect of Fexuprazan 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of Fexuprazan 20 mg.",[30],"NOT_YET_RECRUITING","2026-04-14",{"date":70,"type":44},"2026-04-16",{"date":72,"type":21},"2026-04",{"date":74,"type":21},"2027-12",{"name":76,"class":77},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":52},"100606675","comparing-efficacy-of-bromfenac-009-nepafenac-03-and-diclofenac-01-in-patients-after-cataract-surgery-100606675","NCT07178639","Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery","BND","Inclusion Criteria:\n\n* Are male or female at least 18 years of age who require cataract surgery and no other surgical procedures during the cataract surgery.\n* Agree not to have any other ocular surgical procedures in the study or fellow (non study) eye within 15 days prior to the initiation of dosing with the test article or throughout the duration of the study.\n* Have a Best Corrected Visual Acuity of 20\u002F200 or better in either eye.\n* Are able to self administer test article (or have a caregiver available to instill all doses of test article).\n\nExclusion Criteria:\n\n* Have known hypersensitivity to bromfenac, nepafenac, diclofenac or any component of the test article (including \"procedural\" medications such as anesthetic and\u002For fluorescein drops, dilating drops, etc.).\n* Have intraocular inflammation (i.e., cells or flare in the anterior chamber as measured on slit lamp examination) in study eye at screening visit.\n* Have a known blood dyscrasia or bone marrow suppression, a diagnosis of uncontrolled\u002Funstable peptic ulcer disease, inflammatory bowel disease, or ulcerative colitis, or any uncontrolled\u002Funstable pulmonary, cardiac, vascular, autoimmune, hepatic, renal, or central nervous system disease.\n* Have used ocular, topical, or systemic NSAIDs or ocular, topical, or systemic gentamicin, or cyclosporine ophthalmic emulsion within 7 days prior to initiation of dosing with the test article or throughout the duration of study,with exception of allowing patients on a stable dose of aspirin 81 mg daily or less.\n* Have diabetes of any type.\n* Have any pathology of vitreoretinal interface (recognised on opcital coherence tomography).\n* Have any history of pars plana vitrectomy in the study eye.\n* Have glaucoma of the following types: any secondary, closed angle, severe open angle.\n* Have used ocular prostaglandins within 30 days prior to initiation of dosing with test article or throughout the duration of study.\n* Have active corneal pathology noted in the study eye at screening visit. Active corneal pathology is defined as corneal pathology that is non stable, or greater than mild, or will compromise assessment of the safety or efficacy of treatment. Superficial punctate keratitis in study eye.\n* Have any extraocular\u002Fintraocular inflammation in the study eye at screening visit (blepharitis allowed if mild only, and no concurrent conjunctivitis or lid erythema\u002Fedema) or ongoing, unresolved uveitis.\n* Have used topical, ocular, inhaled or systemic steroids within 14 days prior to screening.\n* Have a history of abuse of alcohol\u002Fdrugs within six months prior to the screening visit.\n* Are pregnant or nursing\u002Flactating.\n* Have participated in any other study of an investigational drug or device within 30 days prior to randomization.",{"count":86,"type":21},150,[24],"The goal of this clinical trial is to learn which of the drugs bromfenac 0.09%, nepafenac 0.3% and diclofenac 0.1% has better efficacy in treatment and prevention of cystoid macular oedema after cataract surgery.\n\nThe main questions it aims to answer are:\n\nWhich of the drugs has better efficacy in macular oedema prevention? What medical problems do participants have when taking different drugs? Researchers will compare drugs to each other.\n\nParticipants will:\n\nTake on of the drugs (randomized) as their treatment in preoperative and postoperative period.\n\nVisit the clinic after the surgery on the first day, first week, in three weeks and in six weeks.\n\nUndergo retina examination with OCT (optical coherence tomography), best vision, and fill in forms considering their quality of life.",[90,91,30],"Macular Oedema","Cataract Surgery",[93,94,95],"macular oedema","cataract surgery","macular oedema treatment","2025-09-10",{"date":98,"type":44},"2025-09-17",{"date":100,"type":44},"2025-08-01",{"date":102,"type":21},"2026-02-28",{"name":104,"class":105},"Nemocnice Kolín","OTHER"]